Oppenheimer raised the firm’s price target on Soleno Therapeutics to $14 from $8 and keeps an Outperform rating on the shares. Clinical results could enable DCCR’s approval for Prader-Willi syndrome approach, Oppenheimer the analyst tells investors in a research note. The firm has greater conviction that the randomized withdrawal study will show a significant difference vs. placebo on the primary endpoint, and expects top-line data in the next 2-3 weeks.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLNO:
- Soleno Therapeutics appoints Matthew Pauls to board of directors
- Soleno Therapeutics reports Q2 EPS (81c), consensus (83c)
- SLNO Upcoming Earnings Report: What to Expect?
- Soleno Therapeutics to participate in a conference call with Cantor Fitzgerald
- Soleno Therapeutics files to sell 22.6M shares of common stock for holders